New combo therapy targets aggressive leukemia transformation

NCT ID NCT04679012

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times

Summary

This study tests a drug called polatuzumab vedotin combined with standard chemotherapy for people whose chronic lymphocytic leukemia has turned into a more aggressive form called Richter's transformation. About 20 adults will receive up to six treatment cycles and be monitored for side effects and how well the cancer responds. The goal is to see if this combination can control the disease better than current options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Columbia University Medical Center

    RECRUITING

    New York, New York, 10032, United States

    Contact

    Contact

  • Mount Sinai- Icahn School of Medicine

    RECRUITING

    New York, New York, 10029, United States

    Contact

    Contact

  • Ohio state University

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact

    Contact

  • Weill Cornell Medicine

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.